AUSTIN, Texas, July 14, 2011 /PRNewswire/ -- Convergen LifeSciences , Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents  and The Secretary, U.S. Department of Health and Human Services. The patent  is one of 23 patents, pending or issued worldwide, licensed exclusively to Convergen LifeSciences, Inc. The patent covers CNVN202, a targeted molecular cancer therapy undergoing clinical evaluation in lung cancer patients.
The '468 patent is based upon important discoveries made by a team of researchers from The University of Texas MD Anderson Cancer Center , The University of Texas Southwestern Medical Center  and the National Cancer Institute . The discovery of the 3p21.3 family of tumor suppressor genes has been the subject of more than 20 peer-reviewed scientific publications demonstrating the genes' ability to control key anti-cancer mechanisms. CNVN202 harnesses TUSC2 (FUS1), the most potent inducer of apoptosis among the family of 3p21.3 cancer suppressor genes.
"The patent further solidifies our growing IP portfolio," stated Greg Heinlein, Chief Operating and Financial Officer, Convergen LifeSciences. "Broadly speaking, this patent expands the application of CNVN202 to virtually all cancers and extends the use of our patented technologies to include cancer diagnostic and screening tools."
Data from a phase I clinical